Future Directions in Regenerative Medicine

Date: February 22, 2011
Pages: 184
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F05123FA10CEN
Leaflet:

Download PDF Leaflet

Future Directions in Regenerative Medicine
Big Pharma has begun investing in regenerative medicine: Genzyme in 2008, Pfizer and Novartis in 2009, and Cephalon in 2010. In 3-5 years, investment will reach a “tipping point”, after which no medical industry players will want to be left behind.

This report covers the development of therapies to replace human cells or promote their regeneration: including cell therapies, tissue engineering, drugs, and medical devices. Each company profiled has at least one project in preclinical or Phase I study. Many also have later stage or launched products, which are covered briefly to illustrate the potential of the next generation of candidates.

Scope of this research
  • Understand the concepts behind regenerative medicine, its potential applications, and advantages over traditional medicine.
  • Compare the opportunities and challenges presented by the different therapeutic modalities.
  • Understand the hurdles that must be overcome by regenerative medicine candidates before they can successfully enter the market.
  • Identify emerging technologies that will shape the regenerative medicine industry in the coming years.
  • Identify companies that may be competitors for a market, or alternatively potential partners or investment opportunities.
Research and analysis highlights

The first regenerative cell therapies to generate significant market value (within the next five years) will be based on allogeneic adult cells, and will target tissues that are naturally sheltered from patients’ immune systems.

Autologous cells are not rejected by the patient’s immune system, so are potentially safer than allogeneic cells and more suitable for permanent tissue replacement. “High tech” therapies based on reprogrammed autologous cells (e.g. induced pluripotent stem cells) may still be 20 years from market.

Tissue engineering still faces technical hurdles, including vascularization of grafted tissue and safe breakdown of scaffold materials. Research and regulatory efforts must be coordinated internationally to develop a stronger “evidence base” for regenerative medicine that is accessible and acceptable to all stakeholders.

Key reasons to purchase this research
  • What is regenerative medicine and why are so many companies and investors excited about it?
  • Which companies are currently developing new regenerative treatments and what approaches are they pursuing?
  • What partnerships have been formed to develop new therapies, and where are the opportunities for further deals?
  • What will the next generation of regenerative medicine candidates look like, and which indications will they treat?
  • What hurdles do these candidates face en route to the marketplace?
Table of Contents
About the author
Disclaimer
Executive summary
An introduction to regenerative medicine
Allogeneic regenerative cell therapies
Autologous regenerative cell therapies
Tissue engineering
Regenerative drug molecules
Regenerative devices and implants
The future of regenerative medicine

CHAPTER 1 AN INTRODUCTION TO REGENERATIVE MEDICINE

Summary
Introduction
Cell-based therapies
Tissue engineering
Acellular therapies

CHAPTER 2 ALLOGENEIC REGENERATIVE CELL THERAPIES

Summary
Introduction
Case studies
Advanced Cell Technology
Altrika
Athersys
BetaLogics
BioTime – embryonic progenitor cells
California Stem Cell
Cardio3 Biosciences
Celgene Cellular Therapeutics
Effector Cell Institute
Gamida Cell
Genzyme and Osiris Therapeutics
Geron
International Stem Cell
ISTO Technologies
MediStem – universal donor cells and cord blood transplants
Mesoblast – mesenchymal precursor cells
NeuralStem – fetal neural stem cells
Pfizer
Pluristem Therapeutics
Promethera Biosciences
Proteonomix
ReNeuron Group
Saneron CCEL Therapeutics.
Stematix
StemCells
Stemedica Cell Technologies
Stempeutics Research
TiGenix – allogeneic MSCs
TissueGene
Summary of allogeneic cell therapies in development
Discussion
Technical issues
Regulatory issues
Logistical issues
Conclusions

CHAPTER 3 AUTOLOGOUS REGENERATIVE CELL THERAPIES

Summary
Introduction
Case studies
Aastrom Biosciences
Aldagen
American Medical Systems Holdings
Amorcyte
Azellon
Bioheart
BioTime – induced pluripotent stem cells
BrainStorm Cell Therapeutics
Cytori Therapeutics
Ectycell
GeneGrafts
GlaxoSmithKline
Intercytex
LoneStar Heart – regenerative cell induction
MedCell Bioscience
MediStem – Tolerostem
MultiGene Vascular Systems
Novartis – monocyte derived islet cells
StemSave
TCA Cellular Therapy
Tissue Genesis Inc.
TriStem
Summary of autologous cell therapies in development
Discussion
Technical issues
Regulatory issues
Logistical issues
Conclusions

CHAPTER 4 TISSUE ENGINEERING

Summary
Introduction
Case studies
Advanced BioHealing
CellSeed
Cerco Medical
Cytograft Tissue Engineering
Japan Tissue Engineering Company
Living Cell Technologies
Lonza Group and Regenicin
Organogenesis
Organovo
Pervasis Therapeutics
Tengion
ViaCyte
Summary of tissue engineering treatments in development
Discussion
Technical issues
Regulatory issues
Logistical issues
Conclusions

CHAPTER 5 REGENERATIVE DRUG MOLECULES

Summary
Introduction
Case studies
Angion Biomedica
Cardio3 Biosciences
DeveloGen
DiaMedica
ImmuneRegen BioSciences
Epistem
Fate Therapeutics
Juventas Therapeutics
LoneStar Heart – cardiac stem cell modulators
Mesoblast – SDF-1
NeuralStem – NSI-189
NeuroNova
Novartis – TherAtoh
Olympus Biotech
Sanofi-Aventis
Stryker
Stem Cell Therapeutics
Tissue Repair Company
Trillium Therapeutics
Summary of regenerative drug molecules in development
Discussion
Technical issues
Regulatory issues
Logistical issues
Conclusions

CHAPTER 6 REGENERATIVE DEVICES AND IMPLANTS

Summary
Introduction
Case studies
Alacer Biomedical
Kensey Nash
Mesynthes
Nanotope
Neopec
Neotherix
RepRegen
TheraGlass
TiGenix – biomaterials
Tissue Regenix Group
Summary of regenerative devices in development
Discussion
Technical issues
Regulatory issues
Logistical issues
Conclusions

CHAPTER 7 THE FUTURE OF REGENERATIVE MEDICINE

Summary
Introduction
Investment in regenerative medicine
Reimbursement
Hope versus hype
Appendix
Scope
Methodology
Primary research
Secondary research
Abbreviations
References
Company websites
Journal and magazine articles
Patent documents

TABLE OF FIGURES

Figure 1: Allogeneic regenerative cell therapy
Figure 2: Autologous regenerative cell therapy
Figure 3: Tissue engineering
Figure 4: NovoGen bioprinting
Figure 5: Regenerative drug therapy
Figure 6: Regenerative medical device therapy

TABLE OF TABLES

Table 1: Allogeneic regenerative cell therapies under development (part 1)
Table 2: Allogeneic regenerative cell therapies under development (part 2)
Table 3: Allogeneic regenerative cell therapies under development (part 3)
Table 4: Allogeneic regenerative cell therapies under development (part 4)
Table 5: Allogeneic regenerative cell therapies under development (part 5)
Table 6: Allogeneic regenerative cell therapies under development (part 6)
Table 7: Autologous regenerative cell therapies under development (part 1)
Table 8: Autologous regenerative cell therapies under development (part 2)
Table 9: Autologous regenerative cell therapies under development (part 3)
Table 10: Autologous regenerative cell therapies under development (part 4)
Table 11: Tissue engineering treatments under development (part 1)
Table 12: Tissue engineering treatments under development (part 2)
Table 13: Regenerative drug molecules under development (part 1)
Table 14: Regenerative drug molecules under development (part 2)
Table 15: Regenerative drug molecules under development (part 3)
Table 16: Regenerative devices under development (part 1)
Table 17: Regenerative devices under development (part 2)
Skip to top


Regenerative Medicine: Market Research Report US$ 4,950.00 Jan, 2014 · 320 pages
Global Regenerative Medicine Market US$ 1,200.00 Dec, 2011 · 105 pages
Soft Drinks 2010 Trends and Future Directions US$ 2,000.00 Apr, 2011 · 31 pages

Ask Your Question

Future Directions in Regenerative Medicine
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: